# Review Article: Lung Cancer Pathophysiology using CRISPR Technology

Mohammed Subhi Mohammed[1], Rana Ahmed Najm[2] and Ameer Ali Imarah[3]
[1]Kufa Technical Institute, Al-Furat Al-Awsat Technical University, Al-Najaf, IRAQ
[2]Kufa Technical Institute, Al-Furat Al-Awsat Technical University, Al-Najaf, IRAQ
[3]Department of Biology, Faculty of Science, University of Kufa, IRAQ

[1]Corresponding Author: mohammed.mohammed@atu.edu.iq

**ABSTRACT**

According to the World Health Organization, respiratory disorders, such as "influenza infection, acute tracheal bronchitis, TB, chronic obstructive pulmonary disease, lung cancer, and nasopharyngeal carcinoma", have a major influence on human health. While environmental and socioeconomic variables might impact the pathogenesis of lung and respiratory tract diseases, it is nevertheless important to further investigate genetic and epigenetic reasons since a great many respiratory illnesses have a genetic or epigenetic basis. CRISPR is made up of interspaced, regularly-spaced palindromic repeated sequences and related proteins that carry out the CRISPR system's duties, which are found in prokaryotes' immune systems. This technology may be used to target, alter, and control genes, making it essential in respiratory research. Cas9 systems enable preclinical modelling of causative variables implicated in respiratory disorders, to generate fresh insights into its operations. CRISPR is also used to hunt for respiratory functions and pathology-associated genes. Which may lead to the discovery of new disease causes or therapeutic targets. The genetic and epigenetic mutations and the disease-associated mutations could be edited using CRISPR/Cas9. This kind of personalised medicine, which might be combined with stem cell reprogramming and transplantation are additional methods, that support embryonic stem cell expansion, might lead to the creation of novel respiratory illness treatment options. The new and developing area of investigation of CRISPR gene editing is one that requires further study the challenges of its specialty and the need for effective and safe delivery strategies. In respiratory health research and treatment, CRISPR systems represent an important step forward, and the discoveries made possible by this technology are likely to continue.

*Keywords-* CRISPR, Cas9, pathology associated genes, lung cancer.

## I. INTRODUCTION

Many individuals have issues with their quality of life due to upper respiratory tract issues, including nose, throat, bronchi, lungs, and the pleural cavity. Common respiratory diseases fall into three broad categories, Examples of relatively mild disorders include "Chronic obstructive lung disease (COPD), acute bacterial and viral infections, asthma and lung and nasopharyngeal malignancies". Asthma, lung and nasopharyngeal malignances are instances of considerably harsher situations, such as acute bacterium and viral infection (COPD), chronic respiratory illness[1-3]. Surfactant protein deficiency, CF, AAT and a number of other unique monogene illnesses have little or no influence on health and life of the patient. Environmental variables such as cigarettes tobacco, air pollution, infections, somatic or inherited genetic abnormalities and the effect of ageing are all issues to consider because of the vast variety of diseases that may emerge. As genetic risk factors contributing to the respiratory disease increase the knowledge[4-6], new technologies are needed to alter the genetic material and modulate endogenous gene expression. The availability of gene editing techniques enables preclinical models to examine the role of certain genes in respiratory physiology and pathology, which may lead to future therapies for respiratory illnesses.

However, newly emerging technologies, including homologous recombination and site-directed nucleases, have been based on small nucleic acid molecules that are able to bind specific DNA sequences, such as ZFNs and TALEN.

One newer system, the CRISPR-Cassystem, has added a significant dimension to the genetic-modification technology. Prokaryotic adaptive immune systems CRISPR functions as an immune system that detects and eliminates viruses and plasmids[7-9], using an RNA-guided method of target recognition. Cas9 system found in Streptococcus pyogenesand described by study authors as a "programmable, efficient, and specific DNA editing" might be reused for a number of uses. For some time, this has been implemented for the purpose of editing the endogenous genes of different cell types and species. To take use of the wide variety of CRISPR systems found in species other than S. pyogenes[10], many of which provide different advantages in terms of gene editing specificity, targeting flexibility, and delivery simplicity, researchers are only starting to do

so. Other than the already mentioned use of CRISPR systems[11-13], the methods included using the Cas9 system for gene editing. CRISPR systems were employed for the transformation and confirmation of the relevance of gene variations associated with respiratory illnesses, as well as for the modulation of gene sequences and the rapeutical expression[14-15]. CRISPR also has the potential to be widely used in respiratory research in the future, particularly for disease-associated genes, since it is a quick and easy technique to screen for them. The following portion will focus on how CRISPR systems in prokaryotes are detected and functioned and how they have been transformed into a gene editing tool[16-18]. In the publication, we analyse uses of CRISPR editing in breathing research and potential hindrances to their wider use, especially the CRISPR methodology.



**Figure 1: CRISPR systems with recurs frequently, although the repeats are separated by gaps that are palindromic have been used to treat respiratory illness.**

## II. METHODOLOGY OF CRISPRSYSTEMS

When a new pathogen is detected, proto-spacers made up of the pathogen's nucleic acid fragments, also referred to as protospacers, are incorporated into CRISPR adaptation proteins edit the bacterial host genome, resulting in a CRISPR array. As the virus enters the second stage of infection, to make CRISPR RNA, the whole array is transcribed and processed (crRNA)[19-21]. Each array incorporates a unique complementary RNA (cRNA) that makes it possible for the host to identify pathogen nucleic acids that have a similar sequence to the RNA first introduced into the array. Target sequence binding (through Watson–Crick base pairing) initiates Cas protein nuclease cleavage of foreign DNA or RNA elements, as is shown in the pathogen Cas end nuclease binding to crRNA and crRNA binding corresponding target sequences.

Although CRISPR systems of different kinds exist, the endonuclease Cas9 from the bacteria Staphylococcus pyogenes is the most widely used for gene editing applications thus far[22]. The Cas9 complex has the crRNA ligated to a transactivatingcrRNA, both of which are delivered to the target DNA regions by the short mRNA molecule referred to as a "transactivatingcrRNA" (tracrRNA)[23-25]. This Cas9 protein only detects and is programmed to cleave DNA targets that complement the crRNA and are located just upstream of the PAM consists of NGG. Cas9 cuts the DNA when it detects the proper DNA target, causing a DNA DSB three base pairs upstream of the PAM. To make matters simpler, the non-coding RNA strand, known as tracrRNA, was replaced with a chimeric single-guide RNA molecule[26-28], which is more easily designed and synthesised than the complicated non-coding RNA strand, known as crRNA-tracrRNA. The DNA cutting enzyme Cas9 protein and a targeting oligonucleotide produced a nuclease that

is designed to induce a DSB throughout the genome, with an accuracy comparable to the NGG.

Involving the elucidation of the mechanism of the S. pyogenes Cas9, which allows it to target bacterial cells, later it was discovered that the S. pyogenes Cas9 system may also be used for gene editing in human cells[29-31]. Cas9-triggered DNA double-strand breaks (DSBs) may be used for gene editing via two different routes. Non-homologous end joining (NHEJ) is the most often utilised DNA repair mechanism. The faulty ones are naturally error-prone and are very likely to produce random insertions and deletions. We may infer that CRISPR-mediated gene re-parations often produce nonsense, since these examples have resulted in functional gene deletion. HDR is a method of DNA repair which utilises the cell's existing templates as donors, and the pathways of which it is a part when a cell has an accessible DNA donor[32-36]. This method includes progression modifications that are taken from applied to the host DNA using the donor template. Cas9, artificial DNA donor molecules, and sgRNA are all delivered together with the possibility of specific sequence target identification and potential for more gene editing using Cas9[37]. In addition, the newly reported Cas13 proteins may be utilised to specifically target RNA for RNA interference modifications and the number of unintended changes is theoretically smaller than for traditional RNA interference[38]. Despite the many CRISPR systems discovered, the biological variety that they represent has yet to be completely investigated and will no doubt provide many new innovations in the near future.

Crispr systems have played a critical role in molecular biology, contributing much to the advancements in this area. Each new DNS goal sequence has to be designed, manufactured, selected and validated for new DNA-binding and time demanding protein domains[39-41], for ZFN and for TALEN to find targets via protein-DNA interactions. A simple, additional base pair between the crRNA and a CRISPR system DNA strand is used for the identification of the target, while the non-complementary basis pairing between crRNA and DNA strand is needed to regulate a crRNA-reliant[42-43] constraint in Cas systems. Different Cas proteins may be employed with different DNA target sequences using the same Cas protein with each new target simply needing the production of a fresh crRNA or sgRNA. The introduction of this capability has dramatically decreased the time, cost, and expertise necessary to carry out gene editing workflows[44]. This section summarises how CRISPR systems have been used in respiratory research and medicine and screening and therapeutic applications.



**Figure 2: The CRISPR Next-generation gene editing technologies uses arranged at regular intervals and punctuated by palindromic repeating groups repeats.**

## III. LUNG CANCER MODELLING

When it comes to using computer modelling to represent and study the characteristics of cancerous lungs, the complexity has always been a substantial obstacle. That said, new methods that use CRISPR have helped researchers produce more customizable and models that may be trusted for research use[45-47]. Tumor

suppression may be knocked down by an anticancer drug that depletes tumour suppressor proteins led to the development of molecularly modelled carcinomas, which are physically and functionally analogous to genuine tumours. The use of Cas9 for gene deletion has proven particularly successful utilising NHEJ. AsgRNA library to carry the afore described sgRNAs was successfully removed from all tumour-suppressor genes to inactivate the genes. In addition to being deployed on

its own[48-49], CRISPR was utilised alongside other gene editing methods, such as Crerecombinase. In these experiments, researchers activated the KrasG12D gene with Cre expression, which provided KrasG12D-expressing cells to the mice[50]. Next, the researchers edited major tumour suppressor genes using CRISPR-based gene editing, and this activation system successfully created functional adenocarcinomas in the mice's lungs.

**Table 1: Various methods have been used to simulate lung cancer in vitro and in vivo**

| Target cell | Approach | Disease | Gene | Alteration | Delivery |
|---|---|---|---|---|---|
| h HEK-293 | In-vitro | Lung Adenocarcinoma | CD74-ROS1, EML4-ALK, KIF5B-RET | Chromosomal rearrangement | Plasmid transfection |
| Mouse lung cells | In-vivo | Lung Adenocarcinoma | Nkx2.1, Pten, Apc | Loss of function | Lentiviral |
| Mouse lung cells | In-vivo | NSCLC | GeCKO library | Loss of function | Lentiviral |
| Endothelial cells and neurons | In-vivo | Lung Adenocarcinoma | Kras, p53, Lkb1 | Loss of function and site-directed mutagenesis | Lentiviral, AAV |
| Mouse lung cells | In-vivo | NSCLC | Eml-Alk | Chromosomal rearrangement | Adenoviral |
| Mouse lung cells | In-vivo | NSCLC | Eml-Alk | Chromosomal rearrangement | Lentiviral |

***Clinical studies of Lung cancer Crispr-based gene therapy***

CRISPR is a tremendously strong and potentially groundbreaking gene therapy technology. Although CRISPR genome editing is very effective, few current human clinical studies are employing it, mainly because few current projects have been given the go-ahead to perform clinical trials. Until far, CRISPR has mostly been employed in the laboratory to change the genomes of cells in a test tube[51-53]. Despite the 13 published clinical studies throughout the globe using CRISPR for the treatment of cancer, there are still a number of these studies going on that have not yet been reported. Only one research on cancer cell gene editing has been conducted[54]. That was done by giving CRISPR Systems to the body, and a systematic review of all studies confirms that in vivo treatment did successfully alter all mentioned cancer cell genes. In addition, the other twelve Cas9-mediated Cancers clinical trials were tested as a cancer treatment. Two techniques have been frequently used in ex vivo gene editing investigations. It aims to improve T-cell efficacy by removing genes from T-lymphocytes[55] that impede their targeting efficiency. The second strategy involves attaching chimeric antigen receptors to the surfaces of T-lymphocytes, which are specific to antigens found on malignant cells, in order to enhance targeting specificity and efficiency.

The PD-1 knockout engineered T cells study, which Sichuan University is doing, is presently ongoing

and is evaluating the safety of the PD-1 knockout T cells in treating metastatic non-small cell lung cancer[56-58]. This research may be placed into one of the previously indicated categories. At the core of this work is the PD-1, programmed gene that only expresses cell death as an immunological checkpoint and has only been proven to activated T-cells. When PD-1 interacts with PD-1 ligands, the process of T-cell death is triggered[59-60]. Antigen presenting cells are usually discovered to have PD-1 ligands on them. The PD-1 pathway interferes with T cell receptor signalling to prevent an overreaction of the immune system. Since knocking down the PD-1 gene will expand the T-cells' longevity and avoid their demise when activated, by removing the T-cell cycle checkpoint inhibitor[61-63], it can be concluded that doing so would help prolong the life of the T-cells. In addition, it would thus have the effect of boosting the number of T-cells that are active in the blood, so boosting the tumor's susceptibility.

The researchers would take autologous T-cells from the peripheral blood and use the CRISPR9 technology to selectively knock off the PD-1 gene in vitro for this study[64]. When they've done that, the researchers will increase the quantity of autologous PD-1 knockout T-lymphocytes and choose a group of people from the initial participants who aren't responding to the treatments. The initial stage in the treatment would be to provide Cyclophosphamide three days before T-cell infusion. Three test groups (each with a different amount of PD-1 knockout T cells) would be used to divide the

patients into three groups, each receiving $1\times 10^7$ per kg PD-1 knockout T cells, $2\times 10^7$ per kg PD-1 knockout T cells, and $4\times10^7$ per kg PD-1 knockout T cells. In order to conclude therapy[65], there would be two further cycles in total. The research would go on to examine the responses of the patients to the therapy and any side effects for an additional period of time after the conclusion of therapy.

### Etiology of Lung Cancer

For more than 50 years, researchers have observed a link between tobacco use and lung cancer, and this link continues to dominate the etiologic milieu of this malignant illness. Lung cancer has also been shown to be caused by a variety of other chemicals, many of which were identified in the work environment. It has long been assumed that there is an inherited propensity to the illness, and current research has identified numerous plausible causes as well as a probable method of inheritance for the condition. There has been significant progress in understanding the molecular abnormalities that are present in lung cancer cells in recent years. Both of these well-known models of lung carcinogenesis have been modified to include the results of contemporary research[66]. As the specifics of the carcinogenic process are uncovered, one objective is to find intermediate (preneoplastic) signs of exposure and inherent propensity that will aid in the assessment of the risk of lung cancer in both individuals and populations.

### Pathogenesis of lung cancer

The development of lung cancer is similar to that of other cancers, in which start events triggered by carcinogens result in the first stages of promotion and advancement of the disease, with each step building on the previous. Cigarette smoking both begins and accelerates the development of cancer. The initiating event occurs early in the smoking process, as indicated by the presence of comparable genetic alterations in the present and past smokers. As a consequence, smoking produces a "field impact" on the lung epithelium, resulting in a large number of initiated cells and a higher chance of transformation. As a consequence of the stimulation given by chronic irritation and promoters inherent in cigarette smoke, continued cigarette smoke exposure allows for the accumulation of new mutations[67]. Cancer normally develops after a 20-25-year period of time has passed after the beginning of smoking. After quitting smoking, the chance of developing cancer diminishes, but cancer cells that have already been begun may advance if another carcinogen continues the process.

It is necessary to differentiate between SCLC and NSCLC due to the fact thosethem: i) start from separate cells, (ii) go through distinct pathogenesis processes, and (iii) acquire various genetic alterations. "MYC, BCL2, c-KIT, p53, and RB are often mutated in SCLC, while EGFR, KRAS, CD44, and p16 are often mutated in NSCLC". Depending on their function, all of these genes are tumor suppressors or ontogenesis.

### Classification of invasive lung cancer

This categorization is based on the appearance of the tumor cells under a microscopical microscope. It is critical to distinguish between these two forms of cancer because they develop, spread, and respond to treatment in very different ways.

SCLC accounts for around 10 percent to 15 percent of all lung malignancies. This is the most aggressive and rapidly growing kind of lung cancer among all sorts. Cigarette smoking is highly associated with the development of SCLC. SCLCs proliferate swiftly to several areas throughout the body, and they are most typically detected after they have disseminated far.

The most prevalent kind of lung cancer, NSCLC, accounts for around 85 percent of all occurrences[68]. It is possible to distinguish three forms of NSCLC based on the kind of cells that are detected in the tumor. They are as follows:

• *Adenocarcinomas* are the most frequent kind of non-small cell lung cancer in the United States, accounting for up to 40% of all lung cancer occurrences. However, unlike other types of lung cancers, adenocarcinomas may occur in people who do not smoke, particularly in women. Lung adenocarcinomas are more often seen in the outside or peripheral regions of the lungs. In addition, they have a predilection for lymphatic node expansion and elsewhere. Adenocarcinoma in situ is a kind of adenocarcinoma that occurs in various locations in the lungs and spreads across the previously developed alveolar walls. A chest X-ray may also reveal what seems to be pneumonia. It is becoming increasingly frequent, and it affects more women than it does males. People diagnosed with such lung cancer are more likely than those diagnosed with other kinds.

• Formerly, squamous cell carcinomas were predominant over adenocarcinomas, but now account for around 25%-30% of all cases of lung cancer. Squamous cell malignancies are more common in the middle chest region, namely in the bronchial passages[69]. The majority of the time, this kind of lung cancer remains inside the lung, spreads to lymph nodes, and develops rather big, producing a hollow.

• *Large cell carcinomas,* also known as undifferentiated carcinomas, are the least prevalent kind of non-small cell lung cancer (NSCLC), accounting for 10 percent to 15 percent of all lung malignancies. This kind of cancer is quite likely to spread to, among others, the lymph nodes and other distant regions.

### Treating and interrogating lung tumori genes is with crispr

CRISPR can do numerous sophisticated chromosomal recombinations in addition to knockin and knockouts. This model was used to study the aspects of the rearrangement of Eml4-Alk genes reported for non-small

cell lung carcinomas (NSCLC). The ablation of PTPN2 boosted the effectiveness of immunotherapy by boosting the interferon-mediated effects on growth suppression and antigen presentation. Upregulation of a deubiquitination enzyme, which has been linked to early phases of lung epithelial cell transition and cancer[70], is also a result of the deletion. The regulation of tumor suppressor miR584-3p by FECR in SCLC and NSCLC tissues is a significant factor in lung cancer spreading. The suppression of the miR585-ROCK1 pathway by CRISpr Cas9-based FLI1 gene knock-out resulted in a stop in tumour development.

Another effort led in clinical research at the University of Pennsylvania presently involves the use of autologous NYCE T cells. The NYCE T-cell operation is being carried out. In preclinical in vitro research for this clinical investigation, the human lung cancer cell line A549-ESO-CBG was employed[71]. The efficacy of p53 reactivating chemicals is heavily reliant on the drug's resistance in the patient, which may be addressed by confirming the target using CRISPR-Cas9. Drug resistance is a major challenge for doctors when treating patients with lung cancer. The uPAR (Urokinase plasminogen activator receptor) receptor was knocked out, and lung cancer cells were less resistant to treatments, including 5-FU, Doxorubicin, Cisplatin, and Docetaxel.

The use of Cas13 to pick exceedingly tiny amounts of DNA or RNA is another sector developing. Mutations were discovered using rapid paper-based testing in the liquid sample of non-small cell lung carcinoma patients.

### Future Perspective

The CRISPR device has a bright future ahead of it in cancer biology because it is an adaptive, simple, convenient, and efficient technology. The technology presents a unique approach to cancer therapy that was previously impossible to implement by allowing for genomic alterations in target cells. The variety, efficacy, and adaptability of the technology will make it the ideal type of cancer treatment in the future[72]. In the future, researchers will have an influence on Cancer Biology as a whole by developing well structured strategies and instruments to provide the target cell or tissue with the technical technology and efficient ways and instructions to manage and eliminate off-target impacts of the technology.

## IV.  CONCLUSION

Conventional approaches based on genetic treatment can enable novel discoveries being a very accurate and effective technique in cancer research and CRISPR, can transform them into useful medicines. At the moment, it is thought that CRISPR has several benefits over the other major gene psychotherapy approaches, including "ZFN and TALENs". Though currently existing treatments are only short-term for the body[73], and gradually wear off over time, gene therapy being genetically engineered allows for permanent treatment delivery and is comparable to hard-coding the treatment into the body. This has the potential to generate vaccinations and therapies that last for a lifetime[74]. As of now, CRISPR is only being used in the clinical setting for drug therapies, but in the future, CRISPR might be used to examine the way cells function. Among all the varieties of Cas9, such as dead Cas9 and dead nCas9, we believe that "dead Cas9 and dead nCas9" are especially useful for the testing of cancer cell growth and proliferation pathways and processes. Based on gene therapy techniques, lung cancer has received a significant amount of attention in the medical research community. However, due of the ethical issues that occur with these approaches, the number of therapy options for this condition is still quite limited[75]. The translatability of gene therapy research is anticipated to increase as governments adopt new laws and regulations, paving the way for the launch of a new generation of cancer-fighting medications.

## REFERENCES

[1] Alapati D, Morrisey EE. Gene editing and genetic lung disease. Basic research meets therapeutic application. *Am. J. Respir. Cell Mol. Biol.* 2017; 56: 283–90.

[2] Bai Y, Liu Y, Su Z, Ma Y, Ren C, Zhao R, Ji HL. Gene editing as a promising approach for respiratory diseases. *J. Med. Genet.* 2018; 55: 143–9.

[3] Waryah CB, Moses C, Arooj M, Blancafort P. Zinc fingers, TALEs, and CRISPR systems: a comparison of tools for epigenome editing. *Methods Mol. Biol.* 2018; 1767: 19–63.

[4] Wright AV, Nunez JK, Doudna JA. Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineer- ing. *Cell* 2016; 164: 29–44.

[5] Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, Zhang F. RNA editing with CRISPR-Cas13. *Science* 2017; 358: 1019–27.

[6] Patterson AG, Yevstigneyeva MS, Fineran PC. Regulation of CRISPR-Cas adaptive immune systems. *Curr. Opin. Microbiol.* 2017; 37: 1–7.

[7] Sternberg SH, Redding S, Jinek M, Greene EC, Doudna JA. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. *Nature* 2014; 507: 62–7.

[8] Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA *et al*. Multiplex genome engineering using CRISPR/Cas systems. *Science* 2013; 339: 819–23.

[9] Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nat. Biotechnol.* 2013; 31: 833–8.

[10] Qi LS, Larson MH, Gilbert LA, Doudna JA,

Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* 2013; 152: 1173–83.

[11] Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern- Ginossar N, Brandman O, Whitehead EH, Doudna JA *et al*. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* 2013; 154: 442–51.

[12] Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Iyer EP, Lin S, Kiani S, Guzman CD, Wiegand DJ *et al*. Highly efficient Cas9-mediated transcriptional programming. *Nat. Methods* 2015; 12: 326–8.

[13] Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC *et al*. Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* 2014; 159: 647–61.

[14] Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H *et al*. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature* 2015; 517: 583–8.

[15] Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* 2016; 533: 420–4.

[16] Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS *et al*. In vivo genome editing using *Staphylococcus aureus* Cas9. *Nature* 2015; 520: 186–91.

[17] Kim D, Kim J, Hur JK, Been KW, Yoon S-h, Kim J-S. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. *Nat. Biotechnol.* 2016; 34: 863–8.

[18] Kleinstiver BP, Tsai SQ, Prew MS, Nguyen NT, Welch MM, Lopez JM, McCaw ZR, Aryee MJ, Joung JK. Genome-wide specific- ities of CRISPR-Cas Cpf1 nucleases in human cells. *Nat. Biotech- nol.* 2016; 34: 869–74.

[19] Chu HW, Rios C, Huang C, Wesolowska-Andersen A, Burchard EG, O'Connor BP, Fingerlin TE, Nichols D, Reynolds SD, Seibold MA. CRISPR–Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18. *Gene Ther.* 2015; 22: 822–9.

[20] Stolzenburg LR, Harris A. Microvesicle-mediated delivery of miR-1343: impact on markers of fibrosis. *Cell Tissue Res.* 2018; 371: 325–38.

[21] Zhang YH, Wu LZ, Liang HL, Yang Y, Qiu J, Kan Q, Zhu W, Ma CL, Zhou XY. Pulmonary surfactant synthesis in miRNA-26a-1/miRNA- 26a-2 double knockout mice generated using the CRISPR/Cas9 system. *Am. J. Transl. Res.* 2017; 9: 355–65.

[22] Wu Q, Jiang D, Matsuda JL, Ternyak K, Zhang B, Chu HW. Ciga- rette smoke induces human airway epithelial senescence via growth differentiation factor 15 production. *Am. J. Respir. Cell Mol. Biol.* 2016; 55: 429–38.

[23] Gao X, Bali AS, Randell SH, Hogan BL. GRHL2 coordinates regen- eration of a polarized mucociliary epithelium from basal stem cells. *J. Cell Biol.* 2015; 211: 669–82.

[24] Rosen BH, Chanson M, Gawenis LR, Liu J, Sofoluwe A, Zoso A, Engelhardt JF. Animal and model systems for studying cystic fibro- sis. *J. Cyst. Fibros.* 2018; 17: s28–34.

[25] Borel F, Sun H, Zieger M, Cox A, Cardozo B, Li W, Oliveira G, Davis A, Gruntman A, Flotte TR *et al*. Editing out five *Serpina1* paralogs to create a mouse model of genetic emphysema. *Proc. Natl. Acad. Sci. U. S. A.* 2018; 115: 2788–93.

[26] Kook S, Qi A, Wang P, Meng S, Gulleman P, Young LR, Guttentag SH. Gene-edited MLE-15 cells as a model for the Hermansky-Pudlak syndromes. *Am. J. Respir. Cell Mol. Biol.* 2018; 58: 566–74.

[27] Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W *et al*. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. *Nature* 2014; 516: 428–31.

[28] Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M *et al*. CRISPR- Cas9 knockin mice for genome editing and cancer modeling. *Cell* 2014; 159: 440–55.

[29] Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sanchez-Rivera FJ *et al*. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. *Nat. Med.* 2017; 23: 1362–8.

[30] Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E *et al*. In vivo engineering of oncogenic chromosomal rearrange- ments with the CRISPR/Cas9 system. *Nature* 2014; 516: 423–7.

[31] Sanjana NE, Shalem O, Zhang F. Improved vectors and genome- wide libraries for CRISPR screening. *Nat. Methods* 2014; 11: 783–4.

[32] Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, Fields AP, Park CY, Corn JE, Kampmann M *et al*. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. *Elife* 2016; 5: e19760.

[33] Wu Q, Tian Y, Zhang J, Tong X, Huang H, Li S, Zhao H, Tang Y, Yuan C, Wang K *et al*. In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis. *Proc. Natl. Acad. Sci. U. S. A.* 2018; 115: e3978–86.

[34] Liao S, Davoli T, Leng Y, Li MZ, Xu Q, Elledge SJ. A genetic inter- action analysis identifies cancer drivers that modify EGFR depen- dency. *Genes Dev.* 2017; 31: 184–96.

[35] Han J, Perez JT, Chen C, Li Y, Benitez A, Kandasamy M, Lee Y, Andrade J, tenOever B, Manicassamy B. Genome-wide CRISPR/- Cas9 screen identifies host factors essential for influenza virus replication. *Cell Rep.* 2018; 23: 596–607.

[36] Kim HS, Lee K, Bae S, Park J, Lee CK, Kim M, Kim E, Kim M, Kim S, Kim C *et al*. CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. *J. Biol. Chem.* 2017; 292: 10664–71.

[37] Unniyampurath U, Pilankatta R, Krishnan MN. RNA interference in the age of CRISPR: will CRISPR interfere with RNAi? *Int. J. Mol. Sci.* 2016; 17: 291.

[38] Dixit A, Parnas O, Li B, Chen J, Fulco CP, Jerby-Arnon L, Marjanovic ND, Dionne D, Burks T, Raychowdhury R *et al*. Per- turb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens. *Cell* 2016; 167: 1853–66.e17.

[39] Datlinger P, Rendeiro AF, Schmidl C, Krausgruber T, Traxler P, Klughammer J, Schuster LC, Kuchler A, Alpar D, Bock C. Pooled CRISPR screening with single-cell transcriptome readout. *Nat. Methods* 2017; 14: 297–301.

[40] Hart SL, Harrison PT. Genetic therapies for cystic fibrosis lung dis- ease. *Curr. Opin. Pharmacol.* 2017; 34: 119–24.

[41] Firth AL, Menon T, Parker GS, Qualls SJ, Lewis BM, Ke E, Dargitz CT, Wright R, Khanna A, Gage FH *et al*. Functional gene correction for cystic fibrosis in lung epithelial cells generated from patient iPSCs. *Cell Rep.* 2015; 12: 1385–90.

[42] Jacob A, Morley M, Hawkins F, McCauley KB, Jean JC, Heins H, Na CL, Weaver TE, Vedaie M, Hurley K *et al*. Differentiation of human pluripotent stem cells into functional lung alveolar epithe- lial cells. *Cell Stem Cell* 2017; 21: 472–88.e10.

[43] Stephens CJ, Kashentseva E, Everett W, Kaliberova L, Curiel DT. Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9. *Gene Ther.* 2018; 25: 139–56.

[44] Bjursell M, Porritt MJ, Ericson E, Taheri-Ghahfarokhi A, Clausen M, Magnusson L, Admyre T, Nitsch R, Mayr L, Aasehaug L *et al*. Therapeutic genome editing with CRISPR/Cas9 in a humanized mouse model ameliorates α1-antitrypsin defi- ciency phenotype. *EBioMedicine* 2018; 29: 104–11.

[45] Alton EW, Boyd AC, Davies JC, Gill DR, Griesenbach U, Harrison PT, Henig N, Higgins T, Hyde SC, Innes JA *et al*. Genetic medicines for CF: hype versus reality. *Pediatr. Pulmonol.* 2016; 51: s5–17.

[46] Song J, Cano-Rodriquez D, Winkle M, Gjaltema RA, Goubert D, Jurkowski TP, Heijink IH, Rots MG, Hylkema MN. Targeted epige- netic editing of SPDEF reduces mucus production in lung epithelial cells. *Am.*

[47] Qiu XY, Zhu LY, Zhu CS, Ma JX, Hou T, Wu XM, Xie SS, Min L, Tan DA, Zhang DY *et al*. Highly effective and low-cost MicroRNA detection with CRISPR-Cas9. *ACS Synth. Biol.* 2018; 7: 807–13.

[48] Aalipour A, Dudley JC, Park SM, Murty S, Chabon JJ, Boyle EA, Diehn M, Gambhir SS. Deactivated CRISPR associated protein 9 for minor-allele enrichment in cell-free DNA. *Clin. Chem.* 2018; 64: 307–16.

[49] Martin F, Sánchez-Hernández S, Gutiérrez-Guerrero A, Pinedo- Gomez J, Benabdellah K. Biased and unbiased methods for the detection of off-target cleavage by CRISPR/Cas9: an overview. *Int. J. Mol. Sci.* 2016; 17: 1507.

[50] Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim JS. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonu- cleases and nickases. *Genome Res.* 2014; 24: 132–41.

[51] Kuscu C, Arslan S, Singh R, Thorpe J, Adli M. Genome-wide analy- sis reveals characteristics of off-target sites bound by the Cas9 endonuclease. *Nat. Biotechnol.* 2014; 32: 677–83.

[52] Wu X, Scott DA, Kriz AJ, Chiu AC, Hsu PD, Dadon DB, Cheng AW, Trevino AE, Konermann S, Chen S *et al*. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. *Nat. Biotech- nol.* 2014; 32: 670–6.

[53] Tasan I, Zhao H. Targeting specificity of the CRISPR/Cas9 system. *ACS Synth. Biol.* 2017; 6: 1609–13.

[54] Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* 2016; 529: 490–5.

[55] Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. *Science* 2016; 351: 84–8.

[56] Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* 2018; 36: 765.

[57] Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE. Enhancing homology-directed genome editing by catalytically active and inac- tive CRISPR-Cas9 using asymmetric donor DNA. *Nat. Biotechnol.* 2016; 34: 339–44.

[58] Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology- directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *Elife* 2014; 3: e04766.

[59] Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribo- nucleoproteins. *Genome Res.* 2014; 24: 1012–9.

[60] Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N,

Ranganathan S *et al*. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection.*J. Biotechnol.* 2015; 208: 44–53.

[61] Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA *et al*. Generation of knock-in primary human T cells using Cas9 ribonu- cleoproteins. *Proc. Natl. Acad. Sci. U. S. A.* 2015; 112: 10437–42.

[62] Cui L, Vigouroux A, Rousset F, Varet H, Khanna V, Bikard D. A CRISPRi screen in *E. coli* reveals sequence-specific toxicity of dCas9. *Nat. Commun.* 2018; 9: 1912.

[63] Marangi M, Pistritto G. Innovative therapeutic strategies for cystic fibrosis: moving forward to CRISPR technique. *Front. Pharmacol.* 2018; 9: 396.

[64] Bos AC, van Holsbeke C, de Backer JW, van Westreenen M, Janssens HM, Vos WG, Tiddens HA. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough? *PLoS One* 2015; 10: e0118454.

[65] Ma H, Marti-Gutierrez N, Park S-W, Wu J, Lee Y, Suzuki K, Koski A, Ji D, Hayama T, Ahmed R *et al*. Correction of a pathogenic gene mutation in human embryos. *Nature* 2017; 548: 413–9.

[66] Alton EW, Boyd AC, Cheng SH, Cunningham S, Davies JC, Gill DR, Griesenbach U, Higgins T, Hyde SC, Innes JA *et al*. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibro- sis. *Thorax* 2013; 68: 1075–7.

[67] Alton EW, Boyd AC, Porteous DJ, Davies G, Davies JC, Griesenbach U, Higgins TE, Gill DR, Hyde SC, Innes JA; UK Cystic Fibrosis Gene Therapy Consortium. A phase I/IIa safety and effi- cacy study of nebulized liposome-mediated gene therapy for cystic fibrosis supports a multidose trial. *Am. J. Respir. Crit. Care Med.* 2015; 192: 1389–92.

[68] Alton EW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, Chan M, Conlon S, Davidson HE, Davies JC *et al*. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. *Thorax* 2017; 72: 137–47.

[69] Kleinjan DA, Wardrope C, Nga Sou S, Rosser SJ. Drug-tunable multidimensional synthetic gene control using inducible degron- tagged dCas9 effectors. *Nat. Commun.* 2017; 8: 1191.

[70] Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, Vakulskas CA, Collingwood MA, Zhang L, Bode NM *et al*. Identification of preexisting adaptive immunity to Cas9 proteins in humans. *Nat. Med.* 2019; 25: 249–254.

[71] Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C *et al*. p53 Inhibits CRISPR- Cas9 engineering in human pluripotent stem cells. *Nat. Med.* 2018; 24: 939–46.

[72] Haapaniemi E, Botla S, Persson J, Schmierer B, Taipale J. CRISPR- Cas9 genome editing induces a p53-mediated DNA damage response. *Nat. Med.* 2018; 24: 927–30.

[73] Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, Jones MD, Golji J, Ruddy DA, Yu K, McAllister G *et al*. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. *CancerDiscov.* 2016; 6: 900–13.

[74] Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben- David U, Cook A, Ha G, Harrington WF, Doshi MB *et al*. Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. *Cancer Discov.* 2016; 6: 914–29.

[75] Zalatan JG, Lee ME, Almeida R, Gilbert LA, Whitehead EH, La Russa M, et al. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell. 2015;160:339–50.